{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=62",
    "query": {
      "intervention": "cohort 2",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 7392,
    "total_pages": 740,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=63&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=61&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T18:46:58.207Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02454270",
      "title": "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Lymphocytic, Chronic, B-Cell",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Follicular",
        "Lymphoma, Mantle-Cell",
        "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
      ],
      "interventions": [
        {
          "name": "Part 1 (Dose Escalation): Duvortuxizumab",
          "type": "DRUG"
        },
        {
          "name": "Part 2 (Dose Expansion): Duvortuxizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2015-06-15",
      "completion_date": "2018-07-26",
      "has_results": false,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 6,
      "location_summary": "Detroit, Michigan • New York, New York • Columbus, Ohio + 3 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454270"
    },
    {
      "nct_id": "NCT02556931",
      "title": "Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Chronic Myelomonocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Prolymphocytic Leukemia",
        "Chronic Myeloid Leukemia",
        "Chronic Myeloproliferative Disorders",
        "Multiple Myeloma",
        "Plasma Cell Neoplasm",
        "Plasma Cell Dyscrasia",
        "Myelofibrosis",
        "Polycythemia Vera",
        "Essential Thrombocythemia",
        "Plasma Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 117,
      "start_date": "2015-12",
      "completion_date": "2021-04",
      "has_results": true,
      "last_update_posted_date": "2022-11-03",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02556931"
    },
    {
      "nct_id": "NCT07905001",
      "title": "A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "HR-positive Breast Cancer",
        "HR+/HER2- Breast Cancer",
        "Locally Advanced Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PRT13722",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Imlunestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 242,
      "start_date": "2026-11-16",
      "completion_date": "2029-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 3,
      "location_summary": "Tamarac, Florida • Maumee, Ohio • Fairfax, Virginia",
      "locations": [
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07905001"
    },
    {
      "nct_id": "NCT07758270",
      "title": "Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis (MS) - Relapsing-remitting"
      ],
      "interventions": [
        {
          "name": "Remibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Ocrelizumab (US)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-08-15",
      "completion_date": "2030-08-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07758270"
    },
    {
      "nct_id": "NCT06381466",
      "title": "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dilated Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "AZD0233",
          "type": "DRUG"
        },
        {
          "name": "AZD0233 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 84,
      "start_date": "2024-04-01",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06381466"
    },
    {
      "nct_id": "NCT00848939",
      "title": "Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "treprostinil diethanolamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2008-12",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2012-10-23",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00848939"
    },
    {
      "nct_id": "NCT04101357",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Extensive-stage Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BNT411",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2020-06-19",
      "completion_date": "2024-05-23",
      "has_results": true,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Greenville, South Carolina",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04101357"
    },
    {
      "nct_id": "NCT07201519",
      "title": "Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer Metastatic",
        "Intrahepatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Hepatic Artery Infusion Pump (HAIP)",
          "type": "DEVICE"
        },
        {
          "name": "Standard Treatment",
          "type": "PROCEDURE"
        },
        {
          "name": "Community Treatment",
          "type": "PROCEDURE"
        },
        {
          "name": "Systemic Chemotherapy Standard of Care",
          "type": "DRUG"
        },
        {
          "name": "Standard Of Care targeting driver mutations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Michael J Cavnar, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-01-23",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07201519"
    },
    {
      "nct_id": "NCT06164730",
      "title": "A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heterozygous Familial Hypercholesterolemia",
        "Premature Coronary Heart Disease"
      ],
      "interventions": [
        {
          "name": "VERVE-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 85,
      "start_date": "2024-04-30",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 10,
      "location_summary": "Dothan, Alabama • Pomona, California • Boca Raton, Florida + 7 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06164730"
    },
    {
      "nct_id": "NCT05287568",
      "title": "CC-486 and Venetoclax for Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "CC-486",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 35,
      "start_date": "2022-12-19",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-11-19T18:46:58.207Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05287568"
    }
  ]
}